🟢 ABIVAX is trading 4.11% up — catalyst remains unclear

ABIVAX is trading at €87.30, up 4.11%, with the move’s specific catalyst unclear.

• No clear company-specific announcement explaining the September 30, 2026 move surfaced in the available coverage.
• A recent report says BTIG maintained its Buy rating and $175 target, but does not link that analyst action to the move.
• Major U.S. indices showed only modest gains, which does not establish a broader-market explanation.